International Journal of Infectious Diseases (Nov 2023)

Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study

  • Hiam Chemaitelly,
  • Jeremy Samuel Faust,
  • Harlan M. Krumholz,
  • Houssein H. Ayoub,
  • Patrick Tang,
  • Peter Coyle,
  • Hadi M. Yassine,
  • Asmaa A. Al Thani,
  • Hebah A. Al-Khatib,
  • Mohammad R. Hasan,
  • Zaina Al-Kanaani,
  • Einas Al-Kuwari,
  • Andrew Jeremijenko,
  • Anvar Hassan Kaleeckal,
  • Ali Nizar Latif,
  • Riyazuddin Mohammad Shaik,
  • Hanan F. Abdul-Rahim,
  • Gheyath K. Nasrallah,
  • Mohamed Ghaith Al-Kuwari,
  • Adeel A. Butt,
  • Hamad Eid Al-Romaihi,
  • Mohamed H. Al-Thani,
  • Abdullatif Al-Khal,
  • Roberto Bertollini,
  • Laith J. Abu-Raddad

Journal volume & issue
Vol. 136
pp. 81 – 90

Abstract

Read online

Objectives: We assessed short-, medium-, and long-term all-cause mortality risks after a primary SARS-CoV-2 infection. Methods: A national, matched, retrospective cohort study was conducted in Qatar to assess risk of all-cause mortality in the national SARS-CoV-2 primary infection cohort compared with the national infection-naïve cohort. Associations were estimated using Cox proportional-hazards regression models. Analyses were stratified by vaccination status and clinical vulnerability status. Results: Among unvaccinated persons, within 90 days after primary infection, the adjusted hazard ratio (aHR) comparing mortality incidence in the primary-infection cohort with the infection-naïve cohort was 1.19 (95% confidence interval 1.02-1.39). aHR was 1.34 (1.11-1.63) in persons more clinically vulnerable to severe COVID-19 and 0.94 (0.72-1.24) in those less clinically vulnerable. Beyond 90 days after primary infection, aHR was 0.50 (0.37-0.68); aHR was 0.41 (0.28-0.58) at 3-7 months and 0.76 (0.46-1.26) at ≥8 months. The aHR was 0.37 (0.25-0.54) in more clinically vulnerable persons and 0.77 (0.48-1.24) in less clinically vulnerable persons. Among vaccinated persons, mortality incidence was comparable in the primary-infection versus infection-naïve cohorts, regardless of clinical vulnerability status. Conclusions: COVID-19 mortality was primarily driven by an accelerated onset of death among individuals who were already vulnerable to all-cause mortality, but vaccination prevented these accelerated deaths.

Keywords